LSA
MTNB icon

Lansing Street Advisors’s Matinas BioPharma MTNB Stock Holding History

Lansing Street Advisors’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1
Closed -$1K – 280
2022
Q1 		$1K Buy
+1
New +$552 ﹤0.01% 263

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.48B AUM 34.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arkadios Wealth Advisors
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Bridgeway Capital Management
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return

Lansing Street Advisors's MTNB Position: Q2 2022 in Review

Lansing Street Advisors sold out of Matinas BioPharma (MTNB) in Q2 2022, closing a stake of 1 share — an estimated $1K sold.

Lansing Street Advisors first reported a position in MTNB in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 49 funds tracked by Wall St. Rank hold MTNB as of Q2 2022.

  • Lansing Street Advisors reported no remaining Matinas BioPharma position as of Q2 2022 after selling out during the quarter.
  • Lansing Street Advisors sold 1 Matinas BioPharma share in Q2 2022, an estimated $1K.
  • Lansing Street Advisors first reported a position in Matinas BioPharma in Q1 2022 and held it in 1 quarter.
  • Lansing Street Advisors's Matinas BioPharma position peaked at $1K in Q1 2022.
  • 49 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2022.

Based on Lansing Street Advisors's 13F filing for Q2 2022, filed 8 Aug 2022.